金吾财讯 | 华芢生物-B(02396)今日起招股，拟发行1764.88万股H股，其中10%为香港发售，90%为国际发售，另有15%超额配股权。每股招股价介于38.2港元至51港元，每手200股，入场费10302.88港元。股份预期将于2025年12月22日挂牌上市，华泰国际、中信证券为联席保荐人。以招股价中间价44.6港元计算，预期集资净额约7.09亿港元，拟将其中约61.8%将用于资助集团的核心产品Pro101-1及Pro-101-2的持续临床开发及商业化；约18.8%将用于通过购买与研发及质量控制活动相关的专业设备及仪器来提升集团的研发能力；约6.3%将用于支付集团核心产品以外的PDGF产品用于治疗其他适应症(如新鲜创面、压疮及放射性溃疡)的持续临床前研发的第三方服务费、研发人员费用及原材料成本；约3.1%将用于支付Mes-201、Oli-101及Oli201临床前研发活动的第三方服务费、研发人员费用及原材料成本；约10%用作营运资金及一般公司用途。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.